EUVIMEDEUVIMED entdecken
Crossref

Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma

Shouzheng Wang iD, Tongji Xie, Yan Li, Lei Guo, Jianming Ying iD, Yan Wang, Xuezhi Hao, Xingyuan Wang, Junling Li, Puyuan Xing

Cancer · 15.12.2023 · 129 (24) · 3873-3883

DOI: 10.1002/cncr.34967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 04.08.2023. Verfasst von Shouzheng Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

TP53 mutation heterogeneity should be considered when using TP53 as a predictive biomarker for anti–programmed death (ligand) 1 (PD‐(L)1) monotherapy in lung adenocarcinoma (LUAD). However, whether TP53 variant allele frequency (VAF) should also be considered remains unknown.

Methods

Patients with LUAD from both published research and the local cohort were included to discover and validate the relationship between TP53 VAF and the efficacy of PD‐(L)1 inhibitors. The Cancer Genome Atlas (TCGA) LUAD data were included for genomic, transcriptomic, and tumor microenvironment analysis.

Results

Among 159 patients in the discovery cohort, low TP53 VAF patients (VAF ≤ 25%) experienced significantly longer progression‐free survival (PFS) than both high TP53 VAF (5.4 vs. 3.3 months; p = .021) and TP53 ‐wild‐type patients (5.4 vs. 2.5 months; p = .011). Multivariate Cox regression revealed low TP53 VAF as an independent biomarker of better efficacy. Among 50 patients in the combined validation cohort, median PFS of low TP53 VAF patients was also significantly longer than that of high TP53 VAF patients (12.0 vs. 2.1 months; p = .037). Analyzed with 469 TCGA LUAD samples, low TP53 VAF is associated with significantly higher PD‐L1 expression, enrichment of gene sets related to T‐cell activation, T cell–mediated immunity, and interferon‐γ signaling pathways, and independently associated with more tumor‐infiltrating CD8 + T cells compared with both high TP53 VAF and TP53 ‐wild type.

Conclusions

TP53 VAF should also be considered when using TP53 as a predictive biomarker. Only low TP53 VAF is independently associated with better efficacy of anti–PD‐(L)1 monotherapy, which may result from higher PD‐L1 expression and more tumor‐infiltrating CD8 + T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsHumansB7-H1 AntigenCD8-Positive T-LymphocytesLigandsBiomarkers, TumorGene FrequencyMutationTumor MicroenvironmentTumor Suppressor Protein p53

Stichwörter der Autor:innen

TP53biomarkerimmunotherapylung adenocarcinomavariant allele frequency

Substanzen

B7-H1 AntigenLigandsBiomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China.
  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Shouzheng Wang, Jianming Ying

Zitieren

APA

Wang, S., Xie, T., Li, Y., Guo, L., Ying, J., Wang, Y., Hao, X., Wang, X., Li, J., & Xing, P. (2023). Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma. Cancer, 129(24), 3873-3883. https://doi.org/10.1002/cncr.34967

Vancouver

Wang S, Xie T, Li Y, Guo L, Ying J, Wang Y, et al. Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma. Cancer. 2023;129(24):3873-3883. doi:10.1002/cncr.34967

BibTeX
@article{Wang2023,
  author = {Wang, Shouzheng and Xie, Tongji and Li, Yan and Guo, Lei and Ying, Jianming and Wang, Yan and Hao, Xuezhi and Wang, Xingyuan and Li, Junling and Xing, Puyuan},
  title = {Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {24},
  pages = {3873--3883},
  doi = {10.1002/cncr.34967}
}
Kostenlos starten →